Morbidity and Mortality Weekly Report最新文献

Two Outbreaks of Legionnaires Disease Associated with Outdoor Hot Tubs for Private Use - Two Cruise Ships, November 2022-July 2024. 2022 年 11 月至 2024 年 7 月，两艘游轮发生两起与私人使用的室外热水浴缸有关的退伍军人病症疫情。

Morbidity and Mortality Weekly Report Pub Date : 2024-10-24 DOI: 10.15585/mmwr.mm7342a3

Sooji Lee,Chris Edens,Troy Ritter,Luis O Rodriguez,Kara Tardivel,Natalia A Kozak-Muiznieks,Melisa Willby,Nancy Ortiz,Adam L Cohen,Jessica C Smith

{"title":"Two Outbreaks of Legionnaires Disease Associated with Outdoor Hot Tubs for Private Use - Two Cruise Ships, November 2022-July 2024.","authors":"Sooji Lee,Chris Edens,Troy Ritter,Luis O Rodriguez,Kara Tardivel,Natalia A Kozak-Muiznieks,Melisa Willby,Nancy Ortiz,Adam L Cohen,Jessica C Smith","doi":"10.15585/mmwr.mm7342a3","DOIUrl":"https://doi.org/10.15585/mmwr.mm7342a3","url":null,"abstract":"Legionnaires disease is a serious pneumonia caused by Legionella bacteria. During November 2022-June 2024, CDC was notified of 12 cases of Legionnaires disease among travelers on two cruise ships; eight on cruise ship A and four on cruise ship B. CDC, in collaboration with the cruise lines, initiated investigations to ascertain the potential sources of on-board exposure after notification of the second potentially associated case for each ship. Epidemiologic data collected from patient interviews and environmental assessment and sampling results identified private hot tubs on selected cabin balconies as the most likely exposure source. To minimize Legionella growth, both cruise lines modified the operation and maintenance of these devices by removing the heating elements, draining water between uses, and increasing the frequency of hyperchlorination and cleaning. Hot tubs offer favorable conditions for Legionella growth and transmission when maintained and operated inadequately, regardless of location. Private hot tubs on cruise ships are not subject to the same maintenance requirements as are public hot tubs in common areas. Given the range of hot tub-type devices offered as amenities across the cruise industry, to reduce risk for Legionella growth and transmission, it is important for cruise ship water management program staff members to inventory and assess private balcony hot tubs and adapt public hot tub maintenance and operations protocols for use on private outdoor hot tubs.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"78 1","pages":"950-954"},"PeriodicalIF":0.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Locally Acquired (Autochthonous) Mosquito-Transmitted Plasmodium vivax Malaria - Saline County, Arkansas, September 2023. 2023 年 9 月，阿肯色州萨林县当地获得的（自生性）经蚊子传播的间日疟原虫疟疾。

Morbidity and Mortality Weekly Report Pub Date : 2024-10-24 DOI: 10.15585/mmwr.mm7342a2

Ashleah P Courtney,Bobby L Boyanton,Paige V Strebeck,Keith Blount,Savanna Ledford,Alison D Ridpath,Kimberly E Mace,Cherie Smith,Kelley Garner,Catherine Waters,Michael J Cima,Naveen Patil,Peter D McElroy,Brian H Raphael,Sarah G H Sapp,Yvonne Qvarnstrom,Audrey Lenhart,Alice Sutcliffe,,Theresa M Dulski,Laura Rothfeldt

{"title":"Locally Acquired (Autochthonous) Mosquito-Transmitted Plasmodium vivax Malaria - Saline County, Arkansas, September 2023.","authors":"Ashleah P Courtney,Bobby L Boyanton,Paige V Strebeck,Keith Blount,Savanna Ledford,Alison D Ridpath,Kimberly E Mace,Cherie Smith,Kelley Garner,Catherine Waters,Michael J Cima,Naveen Patil,Peter D McElroy,Brian H Raphael,Sarah G H Sapp,Yvonne Qvarnstrom,Audrey Lenhart,Alice Sutcliffe,,Theresa M Dulski,Laura Rothfeldt","doi":"10.15585/mmwr.mm7342a2","DOIUrl":"https://doi.org/10.15585/mmwr.mm7342a2","url":null,"abstract":"A case of locally acquired (autochthonous) mosquito-transmitted Plasmodium vivax malaria was diagnosed in Arkansas in September 2023. This represents the 10th autochthonous case identified nationally in 2023, after 20 years without recorded local mosquitoborne malaria transmission in the United States. The public health response included case investigation, active case surveillance, mosquito surveillance and control, assessment of medical countermeasures, and clinical and public outreach. Prompt diagnosis and appropriate treatment of malaria can improve clinical outcomes and, in addition to vector control, minimize risk for local transmission. Clinicians should consider malaria among patients who have traveled to countries where malaria is endemic, or with unexplained fever regardless of travel history. Although the risk for autochthonous malaria in the United States remains very low, its reemergence highlights the importance of vectorborne disease preparedness and response. Examples of such efforts include improving awareness among clinicians, access to diagnostics and antimalarial medications, and capacity for mosquito surveillance and control. Collaboration and communication among CDC, health departments, local jurisdictions, clinicians, hospitals, laboratories, and the public can support rapid malaria diagnosis, prevention, and control. Before traveling internationally to areas where malaria is endemic, travelers should consult with their health care provider regarding recommended malaria prevention measures, including chemoprophylaxis and precautions to avoid mosquito bites, to reduce both personal and community risk.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"2 1","pages":"646-649"},"PeriodicalIF":0.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages - United States, May 2023-September 2024. 对 SARS-CoV-2 变异株进行基因组监测：Omicron XBB和JN.1系的循环 - 美国，2023年5月至2024年9月。

Morbidity and Mortality Weekly Report Pub Date : 2024-10-24 DOI: 10.15585/mmwr.mm7342a1

Kevin C Ma,Juan Castro,Anastasia S Lambrou,Erica Billig Rose,Peter W Cook,Dhwani Batra,Caelin Cubenas,Laura J Hughes,Duncan R MacCannell,Paritra Mandal,Neha Mittal,Mili Sheth,Casey Smith,Amber Winn,Aron J Hall,David E Wentworth,Benjamin J Silk,Natalie J Thornburg,Clinton R Paden

{"title":"Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages - United States, May 2023-September 2024.","authors":"Kevin C Ma,Juan Castro,Anastasia S Lambrou,Erica Billig Rose,Peter W Cook,Dhwani Batra,Caelin Cubenas,Laura J Hughes,Duncan R MacCannell,Paritra Mandal,Neha Mittal,Mili Sheth,Casey Smith,Amber Winn,Aron J Hall,David E Wentworth,Benjamin J Silk,Natalie J Thornburg,Clinton R Paden","doi":"10.15585/mmwr.mm7342a1","DOIUrl":"https://doi.org/10.15585/mmwr.mm7342a1","url":null,"abstract":"CDC continues to track the evolution of SARS-CoV-2, including the Omicron variant and its descendants, using national genomic surveillance. This report summarizes U.S. trends in variant proportion estimates during May 2023-September 2024, a period when SARS-CoV-2 lineages primarily comprised descendants of Omicron variants XBB and JN.1. During summer and fall 2023, multiple descendants of XBB with immune escape substitutions emerged and reached >10% prevalence, including EG.5-like lineages by June 24, FL.1.5.1-like lineages by August 5, HV.1 lineage by September 30, and HK.3-like lineages by November 11. In winter 2023, the JN.1 variant emerged in the United States and rapidly attained predominance nationwide, representing a substantial genetic shift (>30 spike protein amino acid differences) from XBB lineages. Descendants of JN.1 subsequently circulated and reached >10% prevalence, including KQ.1-like and KP.2-like lineages by April 13, KP.3 and LB.1-like lineages by May 25, and KP.3.1.1 by July 20. Surges in COVID-19 cases occurred in winter 2024 during the shift to JN.1 predominance, as well as in summer 2023 and 2024 during circulation of multiple XBB and JN.1 descendants, respectively. The ongoing evolution of the Omicron variant highlights the importance of continued genomic surveillance to guide medical countermeasure development, including the selection of antigens for updated COVID-19 vaccines.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"60 1","pages":"938-945"},"PeriodicalIF":0.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Notes from the Field: First Locally Acquired Dengue Virus Infections - Pasadena, California, October-December 2023. 现场笔记：首次本地感染登革病毒--2023 年 10 月至 12 月，加利福尼亚州帕萨迪纳。

Morbidity and Mortality Weekly Report Pub Date : 2024-10-24 DOI: 10.15585/mmw.mm7342a4

Matt Feaster,Rudy Patrick,Michael Oshiro,Melody Kuan,Ying-Ying Goh,Manuel Carmona,Sara Y Tartof,Jason Farned,Tristan Hallum,Andrea J Lund,Chris Preas,Sharon Messenger,Vicki Kramer,Mary Danforth,Colten Sheridan

引用次数: 0

QuickStats: Prevalence of Obesity* and Severe Obesity† Among Persons Aged 2-19 Years - United States, 1999-2000 Through 2021-2023§. QuickStats：1999-2000年至2021-2023年美国2-19岁人群中肥胖症*和严重肥胖症†的患病率§。

Morbidity and Mortality Weekly Report Pub Date : 2024-10-17 DOI: 10.15585/mmwr.mm7341a5

引用次数: 0

Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten - United States, 2023-24 School Year. 美国 2023-24 学年幼儿园儿童接种特定疫苗的覆盖率和豁免率。

Morbidity and Mortality Weekly Report Pub Date : 2024-10-17 DOI: 10.15585/mmwr.mm7341a3

Ranee Seither,Oyindamola Bidemi Yusuf,Devon Dramann,Kayla Calhoun,Agnes Mugerwa-Kasujja,Cynthia L Knighton,Jennifer L Kriss,Rebecca Miller,Georgina Peacock

{"title":"Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten - United States, 2023-24 School Year.","authors":"Ranee Seither,Oyindamola Bidemi Yusuf,Devon Dramann,Kayla Calhoun,Agnes Mugerwa-Kasujja,Cynthia L Knighton,Jennifer L Kriss,Rebecca Miller,Georgina Peacock","doi":"10.15585/mmwr.mm7341a3","DOIUrl":"https://doi.org/10.15585/mmwr.mm7341a3","url":null,"abstract":"In the United States, states and local jurisdictions set vaccination requirements for school attendance, conditions and procedures for exemptions from these requirements, grace periods for submitting documentation, and provisional enrollment for students who need more time to be vaccinated. States annually report data to CDC on the number of children in kindergarten who meet, are exempt from, or are in the process of meeting requirements. Data reported by 49 states and the District of Columbia (DC) for the 2023-24 school year were used for national- and state-level estimates of the following measures: complete vaccination with required doses of measles, mumps, and rubella vaccine (MMR), diphtheria, tetanus, and acellular pertussis vaccine (DTaP), poliovirus vaccine (polio), and varicella vaccine (VAR); exemptions from vaccination; and school attendance while meeting requirements. The 2023-24 kindergarten class became age-eligible to complete most state-required vaccinations during the COVID-19 pandemic, after schools had returned to routine in-person learning. Compared with approximated national coverage levels across all reported vaccines for the 2019-20 (95%) and 2022-23 (93%) school years, coverage dropped below 93% for the 2023-24 school year, ranging from 92.3% for DTaP to 92.7% for MMR. Exemptions increased to 3.3%, compared with those during the 2022-23 (3.0%) and 2021-22 school years (2.6%). Coverage with MMR, DTaP, polio, and VAR decreased in 35, 32, 33, and 36 jurisdictions, respectively, compared with the 2022-23 school year. Exemptions increased in 41 jurisdictions, with 14 reporting that >5% of kindergartners had an exemption from one or more vaccine. Efforts by health departments, schools, and providers are needed to ensure that students begin school fully vaccinated.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"8 1","pages":"925-932"},"PeriodicalIF":0.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tobacco Product Use Among Middle and High School Students - National Youth Tobacco Survey, United States, 2024. 初中和高中学生烟草制品使用情况 - 美国全国青少年烟草调查，2024 年。

Morbidity and Mortality Weekly Report Pub Date : 2024-10-17 DOI: 10.15585/mmwr.mm7341a2

Ahmed Jamal,Eunice Park-Lee,Jan Birdsey,Andrenita West,Monica Cornelius,Maria R Cooper,Hannah Cowan,Jia Wang,Michael D Sawdey,Karen A Cullen,Livia Navon

{"title":"Tobacco Product Use Among Middle and High School Students - National Youth Tobacco Survey, United States, 2024.","authors":"Ahmed Jamal,Eunice Park-Lee,Jan Birdsey,Andrenita West,Monica Cornelius,Maria R Cooper,Hannah Cowan,Jia Wang,Michael D Sawdey,Karen A Cullen,Livia Navon","doi":"10.15585/mmwr.mm7341a2","DOIUrl":"https://doi.org/10.15585/mmwr.mm7341a2","url":null,"abstract":"Use of tobacco products in any form is unsafe, and nearly all tobacco product use begins during adolescence. CDC and the Food and Drug Administration (FDA) analyzed data from the 2024 National Youth Tobacco Survey to determine tobacco product use among U.S. middle school (grades 6-8) and high school (grades 9-12) students. In 2024, current (previous 30-day) use of any tobacco product was reported by 10.1% of high school students (representing 1.58 million students) and 5.4% of middle school students (representing 640,000 students). Among all students, e-cigarettes were the most commonly reported tobacco product currently used (5.9%), followed by nicotine pouches (1.8%), cigarettes (1.4%), cigars (1.2%), smokeless tobacco (1.2%), other oral nicotine products (1.2%), heated tobacco products (0.8%), hookahs (0.7%), and pipe tobacco (0.5%). During 2023-2024, among all students, the estimated number who reported current use of any tobacco product decreased from 2.80 to 2.25 million students; e-cigarette use decreased (from 2.13 to 1.63 million students); and hookah use decreased (from 290,000 to 190,000 students). Among high school students, current use of any tobacco product decreased from 12.6% to 10.1% of students, and e-cigarette use decreased from 10.0% to 7.8%. Among middle school students, no statistically significant changes occurred. Evidence-based strategies can help prevent initiation and promote cessation of tobacco product use among U.S. youths.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"19 1","pages":"917-924"},"PeriodicalIF":0.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Notes from the Field: Enhanced Surveillance for Raccoon Rabies Virus Variant and Vaccination of Wildlife for Management - Omaha, Nebraska, October 2023-July 2024. 现场笔记：加强对浣熊狂犬病病毒变种的监控和野生动物疫苗接种管理 - 内布拉斯加州奥马哈，2023 年 10 月至 2024 年 7 月。

Morbidity and Mortality Weekly Report Pub Date : 2024-10-17 DOI: 10.15585/mmwr.mm7341a4

Sydney R Stein,Andrew J Beron,Kathleen M Nelson,Emma Price,Sergio E Rodriguez,Victoria Shelus,Ann Carpenter,Amy R Hess,Cassandra Boutelle,Clint N Morgan,Crystal M Gigante,Christina L Hutson,John D Loy,Duan S Loy,Chad Wetzel,Justin Frederick,Lindsay Huse,Lillian Orciari,Richard B Chipman,Ryan M Wallace,Matthew Donahue,Bryan F Buss

引用次数: 0

Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months - United States, April 2024. 2024 年 4 月美国 8 个月以下婴儿的母体呼吸道合胞病毒疫苗接种和呼吸道合胞病毒抗体 (Nirsevimab) 接收情况。

Morbidity and Mortality Weekly Report Pub Date : 2024-09-26 DOI: 10.15585/mmwr.mm7338a2

Hilda Razzaghi,Emma Garacci,Katherine E Kahn,Megan C Lindley,Jefferson M Jones,Shannon Stokley,Kayla Calhoun,Carla L Black

{"title":"Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months - United States, April 2024.","authors":"Hilda Razzaghi,Emma Garacci,Katherine E Kahn,Megan C Lindley,Jefferson M Jones,Shannon Stokley,Kayla Calhoun,Carla L Black","doi":"10.15585/mmwr.mm7338a2","DOIUrl":"https://doi.org/10.15585/mmwr.mm7338a2","url":null,"abstract":"Respiratory syncytial virus (RSV) is the most common cause of hospitalization among U.S. infants. CDC recommends RSV vaccination for pregnant persons or administration of RSV antibody (nirsevimab) to infants aged <8 months to prevent RSV lower respiratory tract disease among infants. To determine maternal and infant RSV immunization coverage for the 2023-24 RSV season, CDC conducted an Internet panel survey during March 26-April 11, 2024. Among 678 women at 32-36 weeks' gestation during September 2023-January 2024, 32.6% reported receipt of an RSV vaccine any time during pregnancy. Among 866 women with an infant born during August 2023-March 2024, 44.6% reported receipt of nirsevimab by the infant. Overall, 55.8% of infants were protected by maternal RSV vaccine, nirsevimab, or both. Provider recommendation for maternal vaccination or infant nirsevimab was associated with higher immunization coverage, whereas lack of a provider recommendation was the main reason for not getting RSV immunization. The main reason for definitely or probably not getting nirsevimab for infants was concern about the long-term safety for the infant. Activities supporting providers to make RSV prevention recommendations and have informative conversations with patients might increase the proportion of infants protected against severe RSV disease. CDC and the American College of Obstetricians and Gynecologists have resources to assist providers in effectively communicating the importance of immunization.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"22 1","pages":"837-843"},"PeriodicalIF":0.0,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142328949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccination Coverage by Age 24 Months Among Children Born During 2017-2021 - U.S.-Affiliated Pacific Islands. 2017-2021 年期间出生的 24 个月大儿童疫苗接种覆盖率 - 太平洋美属岛屿。

Morbidity and Mortality Weekly Report Pub Date : 2024-09-26 DOI: 10.15585/mmwr.mm7338a4

Ashley Tippins,E M Boyd,Kelsey C Coy,Glodi Mutamba,Jennifer L Kriss

{"title":"Vaccination Coverage by Age 24 Months Among Children Born During 2017-2021 - U.S.-Affiliated Pacific Islands.","authors":"Ashley Tippins,E M Boyd,Kelsey C Coy,Glodi Mutamba,Jennifer L Kriss","doi":"10.15585/mmwr.mm7338a4","DOIUrl":"https://doi.org/10.15585/mmwr.mm7338a4","url":null,"abstract":"Childhood vaccination is one of the most successful public health interventions to improve life expectancy, decrease health care costs, and reduce the spread of preventable diseases. Using data from jurisdictional immunization information systems, vaccination coverage by age 24 months among children born during 2017-2021 in the U.S.-affiliated Pacific Islands was estimated for all vaccines included in jurisdictional programs. Progress toward the U.S. Healthy People 2030 and World Health Organization Immunization Agenda 2030 vaccination goals of ≥90% coverage by age 24 months with recommended vaccines was inconsistently met across jurisdictions. For example, coverage by age 24 months with ≥1 dose of measles, mumps, and rubella vaccine ranged from 68.2% to 91.6% by birth cohort in Federated States of Micronesia and from 87.4% to 96.6% in Palau; coverage with ≥4 doses of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) ranged from 39.6% to 60.6% in Federated States of Micronesia and from 73.4% to 85.4% in Palau. Coverage as of June 1, 2024, increased for all vaccines across all jurisdictions and birth cohorts, indicating catch-up vaccination after age 24 months. For example, coverage with ≥4 doses of DTaP by June 1, 2024, ranged from 74.0% to 84.4% in American Samoa by birth cohort and from 91.6% to 94.8% in Palau. This report is the first comprehensive analysis of trends in childhood vaccination coverage in the U.S.-affiliated Pacific Islands; data in this report can be used to determine where additional efforts are needed to assess reasons for delayed vaccination of children and strategies to mitigate vaccination delays, specific to each jurisdiction.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":"25 1","pages":"854-859"},"PeriodicalIF":0.0,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142328985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0